Med BioGene Posts 2009 Loss of $2.1M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostic test developer Med BioGene, which is working toward commercializing its LungExpress Dx test, earned no revenue in 2009 and took a loss on the year of US$2.1 million, the same amount it lost in 2008.

The Vancouver, BC-based company bumped up its R&D spending by 32 percent last year, from $751,000 in 2008 to $989,000 in 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.